Ascendis Pharma unveils its second TransCon™ offering: YORVIPATH® hits markets in Germany and Austria, targeting chronic hypoparathyroidism in adults.

NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.

Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.

Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.

Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.

RS Oncology Confirms Initial Participant Receives Dosage in Stage 2 Trial (MITOPE) Examining RSO-021 in Malignant Chest Tumor and Lung Metastases Therapy.

Sirius Therapeutics has initiated a first-stage clinical study for an advanced, extended-duration Factor XI siRNA anticoagulant, aimed at addressing thromboembolic conditions.

Takeda Pharmaceuticals and Protagonist Therapeutics have signed a global licensing and partnership deal for the advanced experimental blood disorder medication, Rusfertide.

Jaguar Gene Therapy has received the green light from the FDA to initiate trials on JAG201 targeting a specific genetic variant associated with Autism Spectrum Disorder and Phelan-McDermid Syndrome.

Adaptimmune Reveals FDA Approval of Afami-cel Submission for Advanced Synovial Sarcoma Treatment with Expedited Review.

Sandoz introduces Tyruko® (natalizumab), a first-of-its-kind biosimilar aimed at treating multiple sclerosis, now available in Germany.

Johnson & Johnson has filed an additional request with the FDA for authorization of its DARZALEX FASPRO formula as a therapy option for newly identified multiple myeloma cases eligible for transplant.